Utilizing YM-positive ES-2 ovarian cancer cells as a model, our study demonstrates that the YM fusion acts as an oncogenic driver by activating the YAP1/TEAD transcriptional program, validating the YM fusion as a therapeutic target. The gene discussed is YAP1; the disease is ovarian carcinoma.